1-3 of 3
Mark U. Rarick, MD
Close
Sort by
Journal Articles

Increased Dose Intensity of SGN-33, a Humanized Monoclonal Antibody Targeting CD33, Is Active and Well-Tolerated in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS).

Azra Raza, MD, Joseph G. Jurcic, MD, Gail J. Roboz, MD, Joseph J. Stephenson, MD, Mark U. Rarick, MD, Brent L. Wood, MD, Laurie E. Grove, PA-C, Eric L. Sievers, MD, Jonathan G. Drachman, MD
Journal: Blood
Blood (2006) 108 (11): 4568.
https://doi.org/10.1182/blood.V108.11.4568.4568
Published: 2006
Journal Articles

Phase II Preliminary Results of SGN-30 (Anti-CD30 mAb) in Patients with CD30+ Lymphoproliferative Disorders.

Madeleine Duvic, MD, Youn Kim, MD, Sunil Reddy, MD, Andres Forero-Torres, MD, Lauren C. Pinter-Brown, MD, Mark U. Rarick, MD, John Zic, MD, Sophie Worobec, MD, Neil Korman, MD, Timothy Kuzel, MD, Kimberly Bohjanen, MD, Karen Flessland, Jeremy Barton, MD, Eric Sievers, MD
Journal: Blood
Blood (2006) 108 (11): 2733.
https://doi.org/10.1182/blood.V108.11.2733.2733
Published: 2006
Journal Articles

Preliminary Phase II Results of SGN-30 (Anti-CD30 Monoclonal Antibody) in Patients with Cutaneous Anaplastic Large Cell Lymphoma (ALCL).

Madeleine Duvic, MD, Joy Kunishige, MD, Youn H. Kim, MD, Andres Foreno-Torres, MD, Lauren C. Pinter-Brown, MD, Mark U. Rarick, MD, John Zic, MD, Sophie M. Worobec, MD, Francine Foss, MD, Karen Flessland, Jeremy Barton, MD
Journal: Blood
Blood (2005) 106 (11): 4802.
https://doi.org/10.1182/blood.V106.11.4802.4802
Published: 2005